STOCK TITAN

Lilly Eli & Co - LLY STOCK NEWS

Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.

Overview

Lilly Eli & Co (LLY) is a globally recognized pharmaceutical powerhouse with a heritage that spans nearly a century and a half. Founded in 1876 by Colonel Eli Lilly, the company has consistently transformed scientific research into life‐changing therapies while establishing itself as an authority in pharmaceutical innovation. Operating from its headquarters in Indianapolis, Indiana, Lilly Eli & Co has built a network that spans multiple continents and markets, embodying a commitment to advanced research and manufacturing excellence.

Business Model and Core Competencies

The company generates revenue primarily through the development, production, and global distribution of therapeutic medicines. Its diverse portfolio is underpinned by breakthrough R&D in biotechnology and chemical synthesis. By leveraging strategic investments in research, the company has developed innovative treatments for critical areas such as diabetes, oncology, immunology, and neuroscience. These initiatives not only address significant unmet medical needs but also strengthen its competitive edge in the highly dynamic pharmaceutical sector.

Innovative Research and Development

Lilly Eli & Co excels in turning cutting-edge scientific discoveries into practical, market-ready solutions. The company’s approach integrates state-of-the-art biotechnology, chemical innovation, and genetic medicine – elements that drive its robust R&D engine and pave the way for advances in areas such as targeted cancer therapies, metabolic management, and chronic disease care. Its research programs emphasize both precision medicine and large-scale production, ensuring that new therapies are both effective and accessible.

Global Manufacturing and Supply Chain Excellence

In addition to its research prowess, Lilly Eli & Co has a well-established global manufacturing network. The company has continually expanded its facilities, investing in advanced production capabilities to maintain a reliable supply chain. This commitment to manufacturing excellence helps ensure that high-quality products are delivered efficiently to patients worldwide, reinforcing its reputation as a dependable partner in healthcare.

Market Position and Competitive Edge

As an integrated leader in pharmaceutical technology and therapeutics, Lilly Eli & Co has positioned itself at the intersection of innovation and reliability. The company competes through a blend of long-term research investments, strategic global partnerships, and a relentless focus on improving patient outcomes. Its strong brand legacy and comprehensive portfolio of drugs underline a commitment to scientific excellence and unwavering operational execution.

Commitment to Quality and Patient-Centric Solutions

Quality and trust are central to the company's ethos. With a history of rigorous clinical trials and regulatory approvals, Lilly Eli & Co ensures that its medicines meet the highest standards of safety and efficacy. This patient-centric approach, combined with sustainable manufacturing practices, makes it a reliable source of advanced therapies, fostering long-term trust among healthcare providers and patients alike.

Industry Keywords and Expertise

Industry-specific terms such as pharmaceutical innovation, biotechnology, therapeutics, and advanced manufacturing are integral to understanding the company’s operations. These terms reflect the scientific depth and operational expertise that have allowed Lilly Eli & Co to remain at the forefront of drug discovery and development.

Conclusion

With its rich history, expansive R&D capabilities, and global operational reach, Lilly Eli & Co is a testament to the power of innovation in healthcare. This comprehensive overview highlights not only its diversified business model and advanced research but also its enduring commitment to enhancing patient lives through high-quality, accessible, and effective medicines.

Rhea-AI Summary

Loxo@Lilly, the oncology unit of Eli Lilly, will present new data on pirtobrutinib from the BRUIN Phase 1/2 trial at the ASH Annual Meeting in New Orleans from December 10-13, 2022. Pirtobrutinib is a novel, selective BTK inhibitor for treating various B-cell malignancies such as CLL and MCL. Key presentations will highlight its efficacy and safety in previously treated patients. The updated data cutoff is July 2022, reflecting ongoing research and development in targeted cancer therapies. This data aims to enhance understanding of pirtobrutinib's potential in patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
-
Rhea-AI Summary

Lilly reported Q3 2022 revenue of $6.94 billion, up 2% year-over-year, with strong volume growth offset by lower prices and decreased Alimta revenue due to generics. Key growth products saw a 19% increase, contributing 70% of total revenue. Mounjaro launched successfully, generating $97.3 million in U.S. sales. Q3 EPS rose 32% to $1.61. The company updated its 2022 EPS guidance to $6.50-$6.65 (reported) and $7.70-$7.85 (non-GAAP), citing unfavorable foreign exchange impacts and asset impairment charges. Overall, Lilly continues to advance its pipeline with multiple regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary

Eli Lilly and Company has committed $92.5 million to Purdue University to establish a pharmaceutical manufacturing scholarship program and extend research collaboration. This initiative includes $42.5 million for scholarships aimed at underrepresented students, offering up to 100 annual scholarships with guaranteed internships at Lilly. The renewed five-year collaboration will focus on advancements in drug delivery and genetic medicine, supported by an additional $50 million. This partnership aims to enhance Indiana's pharmaceutical ecosystem and training for future professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2022 financial results on November 1, 2022. The announcement will be followed by a conference call at 9 a.m. Eastern time to discuss the financial performance in detail. Investors and the public can access a live webcast via the company's investor relations website. Lilly continues to innovate in healthcare, enhancing diabetes care, obesity treatments, Alzheimer's, and immune system disorders, benefiting over 47 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Summary

Eli Lilly has announced a definitive agreement to acquire Akouos, valued at $487 million with potential additional payouts of up to $610 million. This acquisition aims to enhance Lilly's gene therapy capabilities for treating hearing loss. Akouos specializes in developing innovative adeno-associated viral gene therapies for inner ear conditions, including its lead candidate AK-OTOF for otoferlin gene mutations. The deal, approved by both companies' boards, secures Lilly a premium of 121% over Akouos's stock price before the announcement, with expectations to close in Q4 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
-
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) declared a dividend of $0.98 per share for Q4 2022, payable on Dec. 9, 2022, to shareholders of record on Nov. 15, 2022. This reflects Lilly’s commitment to returning value to investors. The company emphasizes its dedication to delivering innovative medicines and advancing biotechnology to tackle health challenges. Forward-looking statements are included, covering potential risks and uncertainties in pharmaceutical development that may affect future results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
dividends
Rhea-AI Summary

Eli Lilly (NYSE: LLY) announced that the FDA has granted Fast Track designation for tirzepatide, aimed at treating adults with obesity or overweight related comorbidities. This designation accelerates the drug’s path for FDA submission, with a rolling NDA submission planned based on results from two Phase 3 trials: SURMOUNT-1 and SURMOUNT-2. Positive outcomes from these trials could expedite the approval process. Lilly emphasizes its commitment to addressing obesity, a significant health challenge in the U.S., affecting nearly 100 million adults.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
Rhea-AI Summary

Eli Lilly announced the FDA approval of Retevmo® (selpercatinib) for adult patients with locally advanced or metastatic solid tumors exhibiting a RET gene fusion, after previous treatments or lacking alternatives.

The approval is based on tumor-agnostic data from the LIBRETTO-001 trial, showing a 44% overall response rate across various cancers. The FDA also granted traditional approval for Retevmo in adult patients with non-small cell lung cancer (NSCLC) with RET fusion.

Warnings for Retevmo include hepatotoxicity and interstitial lung disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
-
Rhea-AI Summary

Eli Lilly announced positive results from its Phase 3 trials for lebrikizumab, an IL-13 inhibitor for atopic dermatitis (AD). Responders at Week 16 maintained skin clearance and itch relief after a year of treatment, with similar efficacy between every four weeks and every two weeks dosing. Regulatory submissions to the U.S. FDA and EU EMA are planned for this year. Notably, the trials showed a stable safety profile, with most adverse events being mild to moderate.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) announced its participation in the 2022 European Society for Medical Oncology (ESMO) Congress, scheduled for September 9-13, 2022. The company will present key data on its drugs Verzenio® (abemaciclib) and Retevmo® (selpercatinib). Highlights include interim overall survival results from the Phase 3 MONARCH 3 study for Verzenio in advanced breast cancer, and long-term follow-up data for Retevmo in medullary thyroid cancer and non-small cell lung cancer. These presentations aim to advance understanding and treatment options in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none

FAQ

What is the current stock price of Lilly Eli & Co (LLY)?

The current stock price of Lilly Eli & Co (LLY) is $813.48 as of March 14, 2025.

What is the market cap of Lilly Eli & Co (LLY)?

The market cap of Lilly Eli & Co (LLY) is approximately 725.8B.

What is the primary focus of Lilly Eli & Co?

Lilly Eli & Co is focused on developing, manufacturing, and globally distributing innovative therapeutic medicines across areas like diabetes, oncology, immunology, and neuroscience.

How does the company generate its revenue?

The company generates revenue through its extensive R&D efforts, production of high-quality medicines, and worldwide sales, supported by a robust manufacturing network and strategic global partnerships.

What sets Lilly Eli & Co apart in the pharmaceutical industry?

Its long history of innovation, combined with cutting-edge research, advanced manufacturing capabilities, and a strong commitment to quality, positions Lilly Eli & Co as a trusted and pioneering leader in healthcare.

How does Lilly Eli & Co ensure the quality and safety of its products?

The company follows rigorous clinical trial protocols and regulatory standards, ensuring that every product meets the highest levels of safety and efficacy before reaching patients around the world.

Where is Lilly Eli & Co headquartered?

Lilly Eli & Co is headquartered in Indianapolis, Indiana, and operates an extensive global network to support its manufacturing and research activities.

What role does research and development play at Lilly Eli & Co?

R&D is central to the company’s business model, driving innovation in drug discovery, advanced biotechnology applications, and the development of novel therapies to address critical health challenges.

How does Lilly Eli & Co contribute to global healthcare?

By providing innovative, high-quality medicines across diverse therapeutic areas and maintaining an efficient global distribution network, the company helps improve patient outcomes and supports health systems worldwide.

What are some key industry keywords associated with the company?

Key terms include pharmaceutical innovation, biotechnology, therapeutics, research and development, advanced manufacturing, and clinical excellence.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Stock Data

725.80B
946.07M
0.15%
83.27%
0.8%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS